Trials / Not Yet Recruiting
Not Yet RecruitingNCT07185945
Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Phase II Trial of Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Guru Sonpavde · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, single arm study. All subjects will receive Zanzalintinib 60 mg orally once daily until progression per RECIST 1.1 or intolerable toxicities or patient/investigator decision to discontinue study therapy. Radiology imaging will be performed every 8 weeks for 3 timepoints then every 12 weeks thereafter. A window of ± 7 days may be applied to all study visits to accommodate observed holidays, inclement weather, scheduling conflicts etc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanzalintinib | 60 mg orally once daily |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-05-01
- Completion
- 2029-03-01
- First posted
- 2025-09-22
- Last updated
- 2025-12-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07185945. Inclusion in this directory is not an endorsement.